This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Büchter, D. Articles by Nieschlag, E. Search for Related Content PubMed PubMed Citation Articles by Büchter, D. Articles by Nieschlag, E.

Clinical Trial of Transdermal Testosterone and Oral Levonorgestrel for Male Contraception¹

Institute of Reproductive Medicine and Institute of Clinical Chemistry (A.v.E.), University of Münster, D-48149 Münster, Germany

Address all correspondence and requests for reprints to: Prof. Dr. E. Nieschlag, F.R.C.P., Institute of Reproductive Medicine of the University, Domagkstrasse 11, D-48149 Münster, Germany.

Approaches to hormonal male contraception are predominantly based on injectable testosterone (T) application. As most users would prefer an injection-independent modality, this study was designed to develop a self-applicable hormonal male contraceptive regimen by combining transdermal T with an oral gestagen. Eleven healthy men (23–40 yr old) were treated with oral levonorgestrel and transdermal T for 24 weeks. T was applied daily as a transdermal patch to be worn on the trunk. Levonorgestrel was taken orally at a dose of 250 µg daily up to week 12, followed by 500 µg to week 24 in those volunteers who had not become azoospermic by that time. Within 24 weeks, 2 of 11 volunteers had become azoospermic, and 3 of 11 showed sperm concentrations below 3 million/mL. The sperm concentrations of the remaining volunteers declined, but failed to reach the limit considered compatible with contraception by WHO. Treatment resulted in suppression of LH, FSH, and sex hormone-binding globulin, whereby the volunteers with lower sperm concentrations showed more pronounced suppression than the others. Mean T concentrations remained within the lower limit of normal and on occasions were below this level. There were no complaints of hypoandrogenism. Although mean levels of low density lipoprotein cholesterol, apolipoprotein B, as well as basal and postprandial insulin increased, high density lipoprotein cholesterol and apolipoprotein A-I decreased during the treatment phase. Changes in lipid parameters were normalized within 3 weeks after cessation of medication. Although only 5 of 11 volunteers reached the target sperm counts (<3 million/mL), the study shows that a self-applicable hormonal male contraceptive could be developed.

This article has been cited by other articles:

				V. Mahabadi, J. K. Amory, R. S. Swerdloff, W. J. Bremner, S. T. Page, R. Sitruk-Ware, P. D. Christensen, N. Kumar, Y.-Y. Tsong, D. Blithe, et al. Combined Transdermal Testosterone Gel and the Progestin Nestorone Suppresses Serum Gonadotropins in Men J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2313 - 2320. [Abstract] [Full Text] [PDF]

				S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception Endocr. Rev., June 1, 2008; 29(4): 465 - 493. [Abstract] [Full Text] [PDF]

				C. Wang, Y.-G. Cui, X.-H. Wang, Y. Jia, A. Sinha Hikim, Y.-H. Lue, J.-S. Tong, L.-X. Qian, J.-H. Sha, Z.-M. Zhou, et al. Transient Scrotal Hyperthermia and Levonorgestrel Enhance Testosterone-Induced Spermatogenesis Suppression in Men through Increased Germ Cell Apoptosis J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3292 - 3304. [Abstract] [Full Text] [PDF]

				S. T. Page, J. K. Amory, B. D. Anawalt, M. S. Irwig, A. T. Brockenbrough, A. M. Matsumoto, and W. J. Bremner Testosterone Gel Combined with Depomedroxyprogesterone Acetate Is an Effective Male Hormonal Contraceptive Regimen and Is Not Enhanced by the Addition of a GnRH Antagonist J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4374 - 4380. [Abstract] [Full Text] [PDF]

				K. L. Matthiesson and R. I. McLachlan Male hormonal contraception: concept proven, product in sight? Hum. Reprod. Update, July 1, 2006; 12(4): 463 - 482. [Abstract] [Full Text] [PDF]

				C. Wang, X. H. Wang, A. L. Nelson, K. K. Lee, Y. G. Cui, J. S. Tong, N. Berman, L. Lumbreras, A. Leung, L. Hull, et al. Levonorgestrel Implants Enhanced the Suppression of Spermatogenesis by Testosterone Implants: Comparison between Chinese and Non-Chinese Men J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 460 - 470. [Abstract] [Full Text] [PDF]

				B. D. Anawalt, J. K. Amory, K. L. Herbst, A. D. Coviello, S. T. Page, W. J. Bremner, and A. M. Matsumoto Intramuscular Testosterone Enanthate Plus Very Low Dosage Oral Levonorgestrel Suppresses Spermatogenesis Without Causing Weight Gain in Normal Young Men: A Randomized Clinical Trial J Androl, May 1, 2005; 26(3): 405 - 413. [Abstract] [Full Text] [PDF]

				B.M. Brady, M. Walton, N. Hollow, A.T. Kicman, D.T. Baird, and R.A. Anderson Depot testosterone with etonogestrel implants result in induction of azoospermia in all men for long-term contraception Hum. Reprod., November 1, 2004; 19(11): 2658 - 2667. [Abstract] [Full Text] [PDF]

				M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo A Review of Androgen-Progestin Regimens for Male Contraception J Androl, July 1, 2003; 24(4): 466 - 483. [Full Text] [PDF]

				F. C. W. Wu and A. von Eckardstein Androgens and Coronary Artery Disease Endocr. Rev., April 1, 2003; 24(2): 183 - 217. [Abstract] [Full Text] [PDF]

				S. Ramaswamy, G. R. Marshall, C. R. Pohl, R. L. Friedman, and T. M. Plant Inhibitory and Stimulatory Regulation of Testicular Inhibin B Secretion by Luteinizing Hormone and Follicle-Stimulating Hormone, Respectively, in the Rhesus Monkey (Macaca mulatta) Endocrinology, April 1, 2003; 144(4): 1175 - 1185. [Abstract] [Full Text] [PDF]

				K. L. Matthiesson, D. M. Robertson, H. G. Burger, and R. I. McLachlan Response of serum inhibin B and pro-{alpha}C levels to gonadotrophic stimulation in normal men before and after steroidal contraceptive treatment Hum. Reprod., April 1, 2003; 18(4): 734 - 743. [Abstract] [Full Text] [PDF]

				R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]

				I. T. G. Gonzalo, R. S. Swerdloff, A. L. Nelson, B. Clevenger, R. Garcia, N. Berman, and C. Wang Levonorgestrel Implants (Norplant II) for Male Contraception Clinical Trials: Combination with Transdermal and Injectable Testosterone J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3562 - 3572. [Abstract] [Full Text] [PDF]

				R. A. Anderson, D. Kinniburgh, and D. T. Baird Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649. [Abstract] [Full Text] [PDF]

				A. Narula, Y.-Q. Gu, L. O'Donnell, P. G. Stanton, D. M. Robertson, R. I. McLachlan, and W. J. Bremner Variability in Sperm Suppression during Testosterone Administration to Adult Monkeys Is Related to Follicle Stimulating Hormone Suppression and Not to Intratesticular Androgens J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3399 - 3406. [Abstract] [Full Text] [PDF]

				D. Kinniburgh, H. Zhu, L. Cheng, A.T. Kicman, D.T. Baird, and R.A. Anderson Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men Hum. Reprod., June 1, 2002; 17(6): 1490 - 1501. [Abstract] [Full Text] [PDF]

				A. Kamischke, T. Heuermann, K. Kruger, S. von Eckardstein, I. Schellschmidt, A. Rubig, and E. Nieschlag An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 530 - 539. [Abstract] [Full Text] [PDF]

				H.M. Behre, S. Kliesch, B. Lemcke, S. von Eckardstein, and E. Nieschlag Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone Hum. Reprod., December 1, 2001; 16(12): 2570 - 2577. [Abstract] [Full Text] [PDF]

				W. M. Hair, K. Kitteridge, D. B. O'Connor, and F. C. W. Wu A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5201 - 5209. [Abstract] [Full Text] [PDF]

				S. von Eckardstein, A. Syska, J. Gromoll, A. Kamischke, M. Simoni, and E. Nieschlag Inverse Correlation between Sperm Concentration and Number of Androgen Receptor CAG Repeats in Normal Men J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2585 - 2590. [Abstract] [Full Text] [PDF]

				C. W. Martin, S. C. Riley, D. Everington, N. P. Groome, R. A. Riemersma, D. T. Baird, and R. A. Anderson Dose-finding study of oral desogestrel with testosterone pellets for suppression of the pituitary-testicular axis in normal men Hum. Reprod., July 1, 2000; 15(7): 1515 - 1524. [Abstract] [Full Text] [PDF]

				A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception J. Clin. Endocrinol. Metab., January 1, 2000; 86(1): 303 - 309. [Abstract] [Full Text]